Beca JM - Search Results

1

Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer.

Dai WF, Beca JM, Nagamuthu C, Liu N, de Oliveira C, Earle CC, Trudeau M, Chan KKW. Dai WF, et al. Among authors: beca jm. JAMA Oncol. 2022 Apr 1;8(4):597-606. doi: 10.1001/jamaoncol.2021.8049. JAMA Oncol. 2022. PMID: 35201264 Free PMC article.

2

Cost-effectiveness of intensity-modulated radiotherapy in prostate cancer.

Yong JH, Beca J, McGowan T, Bremner KE, Warde P, Hoch JS. Yong JH, et al. Clin Oncol (R Coll Radiol). 2012 Sep;24(7):521-31. doi: 10.1016/j.clon.2012.05.004. Epub 2012 Jun 15. Clin Oncol (R Coll Radiol). 2012. PMID: 22705100

3

Cost-effectiveness of intensity-modulated radiotherapy in oropharyngeal cancer.

Yong JH, Beca J, O'Sullivan B, Huang SH, McGowan T, Warde P, Hoch JS. Yong JH, et al. Clin Oncol (R Coll Radiol). 2012 Sep;24(7):532-8. doi: 10.1016/j.clon.2012.05.010. Epub 2012 Jun 26. Clin Oncol (R Coll Radiol). 2012. PMID: 22739256

4

Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.

Djalalov S, Beca J, Hoch JS, Krahn M, Tsao MS, Cutz JC, Leighl NB. Djalalov S, et al. J Clin Oncol. 2014 Apr 1;32(10):1012-9. doi: 10.1200/JCO.2013.53.1186. Epub 2014 Feb 24. J Clin Oncol. 2014. PMID: 24567430

5

Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis.

Khor S, Beca J, Krahn M, Hodgson D, Lee L, Crump M, Bremner KE, Luo J, Mamdani M, Bell CM, Sawka C, Gavura S, Sullivan T, Trudeau M, Peacock S, Hoch JS. Khor S, et al. BMC Cancer. 2014 Aug 12;14:586. doi: 10.1186/1471-2407-14-586. BMC Cancer. 2014. PMID: 25117912 Free PMC article.

6

Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in Canada.

Djalalov S, Beca J, Amir E, Krahn M, Trudeau ME, Hoch JS. Djalalov S, et al. Curr Oncol. 2015 Apr;22(2):84-96. doi: 10.3747/co.22.2120. Curr Oncol. 2015. PMID: 25908907 Free PMC article.

7

Cost-effectiveness of pazopanib: an example of improved transparency and accessibility of industry-sponsored economic evaluations through publication in peer-reviewed journals.

Beca J, Chan KK. Beca J, et al. Curr Oncol. 2016 Aug;23(4):e327-9. doi: 10.3747/co.22.2741. Epub 2016 Aug 12. Curr Oncol. 2016. PMID: 27536180 Free PMC article. No abstract available.

8

Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment.

Beca J, Husereau D, Chan KKW, Hawkins N, Hoch JS. Beca J, et al. Pharmacoeconomics. 2018 Jan;36(1):7-15. doi: 10.1007/s40273-017-0583-4. Pharmacoeconomics. 2018. PMID: 29110141 Free article.

9

Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent.

Stevenson JKR, Qiao Y, Chan KKW, Beca J, Isaranuwatchai W, Guo H, Schwartz D, Arias J, Gavura S, Dai WF, Kouroukis CT, Cheung MC. Stevenson JKR, et al. Leuk Lymphoma. 2019 Jun;60(6):1399-1408. doi: 10.1080/10428194.2018.1538509. Epub 2018 Dec 5. Leuk Lymphoma. 2019. PMID: 30516081

10

Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer.

Beca J, Majeed H, Chan KKW, Hotte SJ, Loblaw A, Hoch JS. Beca J, et al. Can Urol Assoc J. 2019 Dec;13(12):396-403. doi: 10.5489/cuaj.5889. Can Urol Assoc J. 2019. PMID: 31039109 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

51 results

Search Page

Filters